Crown Equity Holdings Surges on CRWE-PR.com Network Optimism (OTCMKTS:CRWE, NASDAQ:ITMN)

With the Dow Jones Industrial Average (^DJI) down double digits (-0.14%), we would advise you to take a look at over-the-counter securities ticker symbol (OTCMKTS:CRWE). Crown Equity Holdings Inc stock has surged +68.32% Up 0.0069 generating over seven hundred thirty four thousand shares in the financial market at $0.0170 per share Monday February 10, 2014 Real-time: 12:53PM EST. The Company (www.crownequityholdings.com) offers advertising branding and marketing services as a worldwide online multi-media publisher with is vast digital network of websites. The topic of interest amongst investors surrounding Crown Equity Holdings Inc. is the company developing social networking website services available through its mobile optimized local directory designed to target communities throughout California, Nevada, Canada.

With California’s population estimated at 38,041,430 , and Nevada’s population estimated at 2,758,931 according to the United States Census Bureau 2013 and Canada population estimated at 35,158,300 and rising, this potentially places Crown Equity Holdings Inc in a desirable position. The Company has targeted community news, job inquiry, entertainment, community accessible resources, hotels, suites, restaurants and real estate to name a few. Crown Equity Holdings Inc.s CRWE-PR.com network technology is providing services in common with qualities and features in accordance and/or in similarity to potentially NASDAQ Composite is ticker symbol (NASDAQ:LIVE) LiveDeal, Inc., and ticker symbol (NASDAQ:GRPN) Groupon, Inc..  Crown Equity Holdings Inc’s stock at $0.0170 means the company has surged +1,263.64% since its 52 week low as of September 16, 2013.

Up next in the NASDAQ Composite is ticker symbol (NASDAQ:ITMN). InterMune Inc. stock has surged +11.15% Up 1.35 generating over two point nine million shares in the financial market at $13.48 per share Monday February 10, 2014 Real-time: 1:58PM EST. The Company (www.intermune.com) is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. The topic of interest amongst investors surrounding InterMune Inc. is its strong revenue performance in all of its portfolio from its previously released preliminary Q413 accompanied with  its 2014 initial guidance regarding ASCEND prospectively to be announced this Q214.

Read Full Disclaimer at http://crweselect.com/disclaimer/

Remember: Always do your homework and consult your own financial professional.